Plain-English translation of NCT05918094 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a lower-dose version of a chemotherapy combination works as well as the standard-dose version when paired with sintilimab, an immunotherapy medication that helps your immune system fight cancer. Both groups receive the same immunotherapy drug, but the study group gets lower doses of two chemotherapy drugs (capecitabine and oxaliplatin) while the control group receives the standard higher doses. The goal is to see if the lower-dose approach can be as effective while potentially causing fewer side effects.
Standard chemotherapy for advanced stomach cancer can cause difficult side effects that affect quality of life. Researchers want to know if using lower doses of the chemotherapy drugs—while keeping the immunotherapy—might work just as well but with fewer or milder side effects for patients.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the modified lower-dose or standard-dose chemotherapy combination, each given alongside the immunotherapy medication sintilimab. Treatment involves intravenous infusions every 3 weeks and taking oral chemotherapy pills daily for 14 days of each cycle. You would complete up to 6 cycles of this combination (about 4–5 months), and then you could choose to continue with just the oral chemotherapy and immunotherapy for maintenance treatment, continuing for up to 2 years total. Throughout your participation, you'll have regular blood tests and imaging scans to monitor how you're responding.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China